drugset / Trial / NCT00846781

Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)

NCT00846781 ↗

Phase 3 Terminated 308 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to obtain data on the potential of long-term treatment with denufosol to improve the clinical course of CF lung disease in patients with mildly impaired lung function and to provide CF patients who completed study 08-110 continued access to denufosol.

Timeline

Start
2009-02
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject denufosol Other / unclassified 60 mg Inhaled

Indications